CYP2E1 and head and neck cancer: Our meta-analysis gave an overall OR of 1.96 (95% CI: 1.33-2.90, P < 0.001, PQ = 0.87) for head and neck cancer risk among c2 homozygotes of CYP2E1 RsaI/PstI polymorphism compared with the wild type.